Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Share-based Compensation: 2012-2024

Historic Share-based Compensation for Akebia Therapeutics (AKBA) over the last 13 years, with Dec 2024 value amounting to $7.8 million.

  • Akebia Therapeutics' Share-based Compensation rose 95.69% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 28.83%. This contributed to the annual value of $7.8 million for FY2024, which is 16.55% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Share-based Compensation of $7.8 million as of FY2024, which was down 16.55% from $9.3 million recorded in FY2023.
  • Over the past 5 years, Akebia Therapeutics' Share-based Compensation peaked at $24.5 million during FY2020, and registered a low of $7.8 million during FY2024.
  • Over the past 3 years, Akebia Therapeutics' median Share-based Compensation value was $9.3 million (recorded in 2023), while the average stood at $11.6 million.
  • In the last 5 years, Akebia Therapeutics' Share-based Compensation skyrocketed by 105.12% in 2020 and then crashed by 47.80% in 2023.
  • Over the past 5 years, Akebia Therapeutics' Share-based Compensation (Yearly) stood at $24.5 million in 2020, then dropped by 7.05% to $22.7 million in 2021, then dropped by 21.49% to $17.8 million in 2022, then plummeted by 47.80% to $9.3 million in 2023, then dropped by 16.55% to $7.8 million in 2024.